Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

← catalyst calendar

NCT05751798 · readout ≤ 1,229 d

Sponsored by OSE Immunotherapeutics (industry) · OSE.PA — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

41estimated

Sites

Countries

Belgium, France, Spain

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-12-20

actual

When the study began enrolling

Primary completion

Dec 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2029

estimated

The whole study's end, after follow-up

First posted

2023-03-02

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-04

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Solid Advanced Tumor
Lymphoma
NSCLC (Non-small Cell Lung Cancer)

Interventions

Drug: Part A: OSE-279 100mg
Drug: Part A: OSE-279 300mg
Drug: Part A: OSE-279 600mg
Drug: Part B: OSE-279 600 mg and OSE2101
Drug: Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive
Drug: Part C: OSE-279 600 mg - HLA-A2 positif
Drug: Part C: OSE-279 600 mg - HLA-A2 negative

Primary outcome

what the primary-completion date above is the date OF

Part A: Occurrence of dose limiting toxicity (DLT). Part B: Safety and tolerability of the combination OSE-279/OSE2101. Part C: Overall response rate (ORR) of the combination OSE-279/OSE2101

measured Part A: DLT observation period is defined as the first 21 days after receiving the 1st injection of OSE-279 (Cycle 1) Part B: DLT observation period is defined as the first 6 weeks after receiving the combinaison Part C: Best response

Publications

PMID 42034003 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · OSE.PA's whole pipeline · Catalyst calendar · Every registered study · What changed